PIGHI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 1.364
AS - Asia 1.064
EU - Europa 885
SA - Sud America 187
AF - Africa 44
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.549
Nazione #
US - Stati Uniti d'America 1.343
SG - Singapore 519
IT - Italia 200
HK - Hong Kong 196
CN - Cina 185
BR - Brasile 171
RU - Federazione Russa 122
DE - Germania 114
FR - Francia 107
IE - Irlanda 91
KR - Corea 69
SE - Svezia 59
FI - Finlandia 50
GB - Regno Unito 34
TG - Togo 30
ES - Italia 29
NL - Olanda 19
PL - Polonia 19
VN - Vietnam 19
AT - Austria 13
CA - Canada 11
IN - India 11
BD - Bangladesh 10
BE - Belgio 8
TR - Turchia 8
MX - Messico 7
ID - Indonesia 6
JP - Giappone 6
AE - Emirati Arabi Uniti 5
IQ - Iraq 5
LT - Lituania 5
AU - Australia 4
BH - Bahrain 4
MA - Marocco 4
UA - Ucraina 4
UZ - Uzbekistan 4
AR - Argentina 3
IR - Iran 3
PE - Perù 3
PY - Paraguay 3
VE - Venezuela 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
DZ - Algeria 2
EC - Ecuador 2
JO - Giordania 2
KG - Kirghizistan 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
ZA - Sudafrica 2
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CO - Colombia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GH - Ghana 1
IL - Israele 1
IS - Islanda 1
MG - Madagascar 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
PR - Porto Rico 1
RO - Romania 1
SN - Senegal 1
TN - Tunisia 1
TW - Taiwan 1
Totale 3.549
Città #
Dallas 390
Singapore 245
Chandler 244
Hong Kong 192
Ashburn 123
Dublin 88
Munich 52
Beijing 45
Verona 41
Milan 35
The Dalles 35
Columbus 33
Lomé 30
Madrid 26
Seattle 26
Helsinki 25
Lawrence 22
Princeton 22
Redmond 20
Sindelfingen 18
Amsterdam 16
Los Angeles 16
Turku 16
Wilmington 16
Boston 14
Santa Clara 14
Seoul 14
São Paulo 14
Frankfurt am Main 13
Moscow 12
Warsaw 12
New York 11
London 9
Philadelphia 9
Vienna 9
Brussels 8
Lappeenranta 8
Ann Arbor 7
Nuremberg 7
Shenzhen 7
Guangzhou 6
Pescantina 6
Rome 6
Ancona 5
Bonndorf 5
Brasília 5
Hanoi 5
Ho Chi Minh City 5
Hyderabad 5
Paris 5
Southend 5
Tianjin 5
Tokyo 5
Wroclaw 5
Bentivoglio 4
Bexley 4
Brooklyn 4
Caxias do Sul 4
Charlotte 4
Chennai 4
Curitiba 4
Denver 4
Jakarta 4
Mexico City 4
Ottawa 4
Padova 4
Peschiera del Garda 4
Salt Lake City 4
San Francisco 4
Tappahannock 4
Tashkent 4
Washington 4
Woodbridge 4
Xi'an 4
Zhengzhou 4
Ankara 3
Belo Horizonte 3
Bologna 3
Brescia 3
Caracas 3
Council Bluffs 3
Dhaka 3
Dongguan 3
Fairfield 3
Lauterbourg 3
Levallois-perret 3
Lima 3
Marília 3
Neumünster 3
Norwalk 3
Pesaro 3
Phoenix 3
Rio de Janeiro 3
Roubaix 3
Secaucus 3
Shanghai 3
Sicklerville 3
Taizhou 3
Tower Hamlets 3
Treviso 3
Totale 2.176
Nome #
A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes 139
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 107
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 104
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 100
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 98
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 96
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 95
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 91
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 86
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 86
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 80
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 78
Variation of Forehead Temperature during Routine Working Shift in Hospital Laboratory Personnel: Implications for SARS-CoV-2 Screening 76
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 76
Improved potassium reliability in whole blood through hemolysis detection on the novel GEM Premier 7000 blood gas analyzer 74
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 72
Evaluation of indoor hospital acclimatization of body temperature before COVID-19 fever screening 71
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 71
Monoclonal gammopathy in SARS-CoV-2 infection 64
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 64
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 63
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 61
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 61
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 60
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 60
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 59
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 59
Preanalytical Impact of Incomplete K2EDTA Blood Tube Filling in Molecular Biology Testing 59
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 57
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 56
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 55
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 55
Effect of syringe underfilling on the quality of venous blood gas analysis 54
Cellular immunity against SARS-CoV-2 depends on the serological status 54
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 52
Clinical assessment of Ortho VITROS SARS-CoV-2 antigen chemiluminescence immunoassay 51
Correlation between basal humoral immunogenicity and side effects after receiving the bivalent formulation of a mRNA-based vaccine 50
Limitations of hemolysis-based correction for potassium measurement in hemolyzed whole blood samples 49
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 49
Accuracy of screening for hemolysis in plasma samples using a commercial urine dipstick 48
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 45
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 42
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 41
Evaluating the accuracy of ChatGPT in classifying normal and abnormal blood cell morphology 40
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 40
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 40
Methadone metabolite (EDDP) crystals in urine: a case report 38
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 37
Impact of the COVID-19 pandemic on the volume of laboratory testing 37
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 35
Effect of exogenous lipids contamination on blood gas analysis 35
Analytical validation of hemolysis detection on GEM Premier 7000 35
Impact of an air bubble within the syringe on test results obtained with a modern blood gas analyzer 34
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 34
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 34
Is mixing of blood gas syringes after collection really necessary? 33
Generative artificial intelligence (AI) for reporting the performance of laboratory biomarkers: not ready for prime time 31
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 30
Humoral response is enhanced after ipsilateral double intramuscular injection of BNT162b2 COVID-19 vaccine 29
The incremental impact of comorbidities in COVID-19-related deaths compared to patients dying from cancer or cardiovascular disease 27
Evaluation of circadian rhythm of SARS-CoV-2 interferon-gamma release assay (IGRA) in healthy vaccinated individuals: a case-series 26
Update on Patient Self-Testing with Portable and Wearable Devices: Advantages and Limitations 25
Performance assessment of ChatGPT in classification of urine particles 24
Urine dipstick for screening plasma glucose and bilirubin in low resource settings: a proof-of-concept study 23
Uso de una tira reactiva paraorina en la evaluación de las concentraciones de glucosa y bilirrubina en plasma en entornos con recursos limitados: un estudio de prueba de concepto 18
Totale 3.673
Categoria #
all - tutte 18.156
article - articoli 17.895
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 261
Totale 36.312


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 0 0 0 0 0 2 3 2 17
2021/2022205 29 37 7 8 10 4 4 6 14 8 26 52
2022/2023621 36 51 58 116 31 126 23 54 63 9 29 25
2023/2024433 19 30 29 45 66 48 43 71 4 25 38 15
2024/20251.527 65 84 90 185 61 62 64 87 181 139 225 284
2025/2026863 333 281 249 0 0 0 0 0 0 0 0 0
Totale 3.673